<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36692636</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19.</ArticleTitle><Pagination><StartPage>1823</StartPage><EndPage>1834</EndPage><MedlinePgn>1823-1834</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11543-8</ELocationID><Abstract><AbstractText>Emerging evidence indicates that the etiologic agent responsible for coronavirus disease 2019 (COVID-19), can cause neurological complications. COVID-19 may induce cognitive impairment through multiple mechanisms. The aim of the present study was to describe the possible neuropsychological and metabolic neuroimaging consequences of COVID-19 12&#xa0;months after patients' hospital discharge. We retrospectively recruited 7 patients (age [mean&#x2009;&#xb1;&#x2009;SD]&#x2009;=&#x2009;56 years&#x2009;&#xb1;&#x2009;12.39, 4 men) who had been hospitalized for COVID-19 with persistent neuropsychological deficits 12&#xa0;months after hospital discharge. All patients underwent cognitive assessment and brain (<sup>18</sup>F-FDG) PET/CT, and one also underwent <sup>18</sup>F-amyloid PET/CT. Of the seven patients studied, four had normal glucose metabolism in the brain. Three patients showed various brain hypometabolism patterns: (1) unilateral left temporal mesial area hypometabolism; (2) pontine involvement; and (3) bilateral prefrontal area abnormalities with asymmetric parietal impairment. The patient who showed the most widespread glucose hypometabolism in the brain underwent an <sup>18</sup>F-amyloid PET/CT to assess the presence of A&#x3b2; plaques. This examination showed significant A&#x3b2; deposition in the superior and middle frontal cortex, and in the posterior cingulate cortex extending mildly in the rostral and caudal anterior cingulate areas. Although some other reports have already suggested that brain hypometabolism may be associated with cognitive impairment at shorter intervals from SarsCov-2 infection, our study is the first to assess cognitive functions, brain metabolic activity and in a patient also amyloid PET one year after COVID-19, demonstrating that cerebral effects of COVID-19 can largely outlast the acute phase of the disease and even be followed by amyloid deposition.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ferrucci</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Health Science, Aldo Ravelli Research Center, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, ASST-Santi Paolo e Carlo Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuffaro</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurology Unit, ASST-Santi Paolo e Carlo Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capozza</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Unit, ASST-Santi Paolo e Carlo Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosci</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurology Unit, ASST-Santi Paolo e Carlo Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maiorana</LastName><ForeName>Natale</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Health Science, Aldo Ravelli Research Center, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groppo</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology Unit, ASST-Santi Paolo e Carlo Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitano</LastName><ForeName>Maria Rita</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Neurology Unit, ASST-Santi Paolo e Carlo Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Auxologico Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Auxologico Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tagliabue</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Unit, ASST-Santi Paolo e Carlo Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Auxologico Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priori</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1549-3851</Identifier><AffiliationInfo><Affiliation>Department of Health Science, Aldo Ravelli Research Center, University of Milan, Milan, Italy. alberto.priori@unimi.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, ASST-Santi Paolo e Carlo Hospital, Milan, Italy. alberto.priori@unimi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">18F-amyloid PET/CT</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cognitive function</Keyword><Keyword MajorTopicYN="N">Hypometabolism</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword></KeywordList><CoiStatement>The authors have no relevant financial or non-financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36692636</ArticleId><ArticleId IdType="pmc">PMC9873215</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11543-8</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11543-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Priori A, Senior E, Dini M, Deputy E. Neurology of COVID-19. Milan: Milano university press; 2021.</Citation></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48:2823&#x2013;33. doi: 10.1007/s00259-021-05215-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kas A, Soret M, Pyatigoskaya N, Habert M-O, Hesters A, Le Guennec L, et al. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. 2021;48:2543&#x2013;57. doi: 10.1007/s00259-020-05178-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05178-y</ArticleId><ArticleId IdType="pmc">PMC7810428</ArticleId><ArticleId IdType="pubmed">33452633</ArticleId></ArticleIdList></Reference><Reference><Citation>Miskowiak KW, Johnsen S, Sattler SM, Nielsen S, Kunalan K, Rungby J, et al. Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol Elsevier B.V. 2021;46:39&#x2013;48. doi: 10.1016/j.euroneuro.2021.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2021.03.019</ArticleId><ArticleId IdType="pmc">PMC8006192</ArticleId><ArticleId IdType="pubmed">33823427</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker HA, Safavynia SA, Evered LA. The &#x2018;third wave&#x2019;: impending cognitive and functional decline in COVID-19 survivors. Br J Anaesth. 2021;126:44&#x2013;47. doi: 10.1016/j.bja.2020.09.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2020.09.045</ArticleId><ArticleId IdType="pmc">PMC7577658</ArticleId><ArticleId IdType="pubmed">33187638</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijiala S, Epiney J-B, J&#xf6;hr J, Pincherle A, Meyer MM, Du Pasquier R, et al (2021) Case report: behavioral unresponsiveness in acute COVID-19 patients: the utility of the motor behavior tool-revised and (18)F-FDG PET/CT. Front Neurol 644848</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119781</ArticleId><ArticleId IdType="pubmed">33995248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet Elsevier Ltd. 2020;395:507&#x2013;513. doi: 10.1016/S0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020;77:1018&#x2013;1027. doi: 10.1001/jamaneurol.2020.2065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.2065</ArticleId><ArticleId IdType="pmc">PMC7484225</ArticleId><ArticleId IdType="pubmed">32469387</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218(3):e20202135. doi: 10.1084/jem.20202135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Safavynia SA, Goldstein PA. The role of neuroinflammation in postoperative cognitive dysfunction: moving from hypothesis to treatment. Front Psychiatry. 2019;9:752. doi: 10.3389/fpsyt.2018.00752.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2018.00752</ArticleId><ArticleId IdType="pmc">PMC6345198</ArticleId><ArticleId IdType="pubmed">30705643</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;ndez R, Balanz&#xe1;-Mart&#xed;nez V, Luperdi SC, Estrada I, Latorre A, Gonz&#xe1;lez-Jim&#xe9;nez P, et al. Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med. 2021;290(3):621&#x2013;631. doi: 10.1111/joim.13262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13262</ArticleId><ArticleId IdType="pmc">PMC8013333</ArticleId><ArticleId IdType="pubmed">33533521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021;144:1263&#x2013;1276. doi: 10.1093/brain/awab009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab009</ArticleId><ArticleId IdType="pmc">PMC8083602</ArticleId><ArticleId IdType="pubmed">33822001</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain, Behav Immun - Heal. 2020;9:100163. doi: 10.1016/j.bbih.2020.100163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2020.100163</ArticleId><ArticleId IdType="pmc">PMC7581383</ArticleId><ArticleId IdType="pubmed">33111132</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Lu S, Chen J, Wei N, Wang D, Lyu H, et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res Elsevier Ltd. 2020;129:98&#x2013;102. doi: 10.1016/j.jpsychires.2020.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2020.06.022</ArticleId><ArticleId IdType="pmc">PMC7324344</ArticleId><ArticleId IdType="pubmed">32912598</ArticleId></ArticleIdList></Reference><Reference><Citation>Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie AC, et al. Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol - Lung Cell Mol Physiol. 2020;319:L277&#x2013;L288. doi: 10.1152/ajplung.00195.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00195.2020</ArticleId><ArticleId IdType="pmc">PMC7414237</ArticleId><ArticleId IdType="pubmed">32551862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci R, Dini M, Groppo E, Rosci C, Reitano MR, Bai F, et al. Long-lasting cognitive abnormalities after COVID-19. Brain Sci. 2021;11:1&#x2013;11. doi: 10.3390/brainsci11020235.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11020235</ArticleId><ArticleId IdType="pmc">PMC7917789</ArticleId><ArticleId IdType="pubmed">33668456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer&#x2019;s disease and other dementias. Lancet Neurol England. 2020;19:951&#x2013;962. doi: 10.1016/S1474-4422(20)30314-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30314-8</ArticleId><ArticleId IdType="pubmed">33098804</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazhenets G, Schr&#xf6;ter N, Bormann T, Thurow J, Wagner D, Frings L, et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med. 2021;62:910&#x2013;915. doi: 10.2967/jnumed.121.262128.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262128</ArticleId><ArticleId IdType="pmc">PMC8882885</ArticleId><ArticleId IdType="pubmed">33789937</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, De Caro MF, et al. The Rao&#x2019;s brief repeatable battery and stroop test: normative values with age, education and gender corrections in an Italian population. Mult Scler J Mult Scler. 2006;12:787&#x2013;793. doi: 10.1177/1352458506070933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458506070933</ArticleId><ArticleId IdType="pubmed">17263008</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnarson P&#xd6;, &#xd3;lason DP, Sm&#xe1;ri J, Sigurdsson JF. The Beck depression inventory second edition (BDI-II): psychometric properties in Icelandic student and patient populations. Taylor &amp; Francis. 2009;62:360&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18752106</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, et al. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49:632&#x2013;651. doi: 10.1007/s00259-021-05603-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05603-w</ArticleId><ArticleId IdType="pmc">PMC8803744</ArticleId><ArticleId IdType="pubmed">34882261</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, et al. European association of nuclear medicine and european academy of neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25:1201&#x2013;1217. doi: 10.1111/ene.13728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13728</ArticleId><ArticleId IdType="pubmed">29932266</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskian M, Alavi A, Khorasanizadeh MH, Viglianti BL, Jacobsson H, Barwick TD, et al. Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements. Eur J Nucl Med Mol Imaging. 2019;46:224&#x2013;237. doi: 10.1007/s00259-018-4194-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-4194-x</ArticleId><ArticleId IdType="pubmed">30350009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindstr&#xf6;m E, Oddstig J, Danfors T, J&#xf6;gi J, Hansson O, Lubberink M. Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases. NeuroImage Clin. Elsevier. 2020;28:102386. doi: 10.1016/j.nicl.2020.102386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102386</ArticleId><ArticleId IdType="pmc">PMC7476314</ArticleId><ArticleId IdType="pubmed">32882645</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, et al. SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med. United States. 2016;57:1316&#x2013;22. doi: 10.2967/jnumed.116.174615.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.116.174615</ArticleId><ArticleId IdType="pubmed">27481605</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer&#x2019;s disease. Assess Dis Monit. 2017;9:25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536824</ArticleId><ArticleId IdType="pubmed">28795133</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana IC, Bongarzone S, Gee A, Souza DO, Zimmer ER. PET imaging as a tool for assessing COVID-19 brain changes. Trends Neurosci. 2020;43:935&#x2013;938. doi: 10.1016/j.tins.2020.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.10.010</ArticleId><ArticleId IdType="pmc">PMC7580682</ArticleId><ArticleId IdType="pubmed">33131922</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan K, Premi E, Pilotto A, Cristillo V, Benussi A, Libri I, et al. Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19. Neurobiol Stress. 2021;14:100326. doi: 10.1016/j.ynstr.2021.100326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ynstr.2021.100326</ArticleId><ArticleId IdType="pmc">PMC8041745</ArticleId><ArticleId IdType="pubmed">33869679</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Ling Q, Manyande A, Wu D, Xiang B. Brain imaging changes in patients recovered from COVID-19: a narrative review. Front Neurosci. 2022;16:855868. doi: 10.3389/fnins.2022.855868.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.855868</ArticleId><ArticleId IdType="pmc">PMC9072792</ArticleId><ArticleId IdType="pubmed">35527821</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudroff T, Workman CD, Ponto LLB. 18F-FDG-PET imaging for post-COVID-19 brain and skeletal muscle alterations. Viruses. 2021;13(11):2283. doi: 10.3390/v13112283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112283</ArticleId><ArticleId IdType="pmc">PMC8625263</ArticleId><ArticleId IdType="pubmed">34835088</ArticleId></ArticleIdList></Reference><Reference><Citation>Dressing A, Bormann T, Blazhenets G, Schroeter N, Walter LI, Thurow J, et al. Neuropsychologic profiles and cerebral glucose metabolism in neurocognitive long COVID syndrome.". J Nucl Med. 2022;63:1058&#x2013;1063. doi: 10.2967/jnumed.121.262677.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262677</ArticleId><ArticleId IdType="pmc">PMC9258569</ArticleId><ArticleId IdType="pubmed">34649946</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;lez M, Falcon&#xed; Paez A, Nicolalde B, Esquetini-Vernon C, Lara-Taranchenko Y, Zambrano K, et al. Cognitive impairment or dementia in post-acute COVID-19 syndrome. Two suspects and a perfect detective: positron emission tomography (PET) scan. Eur Neuropsychopharmacol. 2022;61:91&#x2013;93. doi: 10.1016/j.euroneuro.2022.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2022.06.010</ArticleId><ArticleId IdType="pmc">PMC9259455</ArticleId><ArticleId IdType="pubmed">35870344</ArticleId></ArticleIdList></Reference><Reference><Citation>Danics K, Forrest SL, Kapas I, Erber I, Schmid S, T&#xf6;r&#x151; K, et al. Neurodegenerative proteinopathies associated with neuroinfections. J Neural Transm. 2021;128:1551&#x2013;1566. doi: 10.1007/s00702-021-02371-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-021-02371-7</ArticleId><ArticleId IdType="pmc">PMC8255726</ArticleId><ArticleId IdType="pubmed">34223998</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulop T, Witkowski JM, Larbi A, Khalil A, Herbein G, Frost EH. Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer&#x2019;s disease? J Neurovirol United States. 2019;25:634&#x2013;647. doi: 10.1007/s13365-019-00732-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-019-00732-3</ArticleId><ArticleId IdType="pubmed">30868421</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697&#x2013;707. doi: 10.1038/s41586-022-04569-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciaccio M, Lo Sasso B, Scazzone C, Gambino CM, Ciaccio AM, Bivona G, et al. COVID-19 and Alzheimer&#x2019;s disease. Brain Sci. 2021;11:1&#x2013;10. doi: 10.3390/brainsci11030305.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11030305</ArticleId><ArticleId IdType="pmc">PMC7997244</ArticleId><ArticleId IdType="pubmed">33673697</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer&#x2019;s disease. Neurobiol Aging. 2000;21:383&#x2013;421. doi: 10.1016/S0197-4580(00)00124-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00124-X</ArticleId><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Webers A, Heneka MT, Gleeson PA. The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer&#x2019;s disease. Immunol Cell Biol United States. 2020;98:28&#x2013;41. doi: 10.1111/imcb.12301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12301</ArticleId><ArticleId IdType="pubmed">31654430</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouhan JK, P&#xfc;ntener U, Booth SG, Teeling JL. Systemic inflammation accelerates changes in microglial and synaptic markers in an experimental model of chronic neurodegeneration. Front Neurosci. 2021;15:760721. doi: 10.3389/fnins.2021.760721.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.760721</ArticleId><ArticleId IdType="pmc">PMC8764443</ArticleId><ArticleId IdType="pubmed">35058740</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D, Hammi I, Kihel A, El Idrissi SI, Guessous F, Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb Pathog. 2021;153:104799. doi: 10.1016/j.micpath.2021.104799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104799</ArticleId><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Rau A, Schroeter N, Blazhenets G, Dressing A, Walter LI, Kellner E, et al. Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms. Brain: Oxford University Press (OUP); 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214163</ArticleId><ArticleId IdType="pubmed">35675908</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y, Wu J, Chen T, Li J, Zhang G, Wu D, et al (2021) Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J Clin Invest 131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262559</ArticleId><ArticleId IdType="pubmed">33630760</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP, LeVine H., 3rd Alzheimer&#x2019;s disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19:311&#x2013;323. doi: 10.3233/JAD-2010-1221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1221</ArticleId><ArticleId IdType="pmc">PMC2813509</ArticleId><ArticleId IdType="pubmed">20061647</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>